The Multifaceted Influence of RSV on Respiratory Health: Microbiome Dynamics, Macrophage Function, And Probiotic Therapy
No Thumbnail Available
Date
2025
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Saudi Digital Library
Abstract
Respiratory syncytial virus (RSV) remains a leading cause of severe lower
respiratory tract infections in infants, with co-infection by Streptococcus pneumoniae
often contributing to worse clinical outcomes. This thesis investigates the cellular and
microbial dynamics underlying RSV and RSV-pneumococcal co-infection using a
combination of in vitro assays, murine models, and infant clinical samples.
Through in vivo and ex vivo experiments, RSV infection was shown to impair
alveolar macrophage (AMQ) functionality, particularly reducing phagocytic capacity
and promoting M2-like polarisation. Co-infection with S. pneumoniae further
amplified inflammation and bacterial dissemination. However, treatment with Bacillus
subtilis spores significantly enhanced the recruitment of tissue-resident AMQs,
improved bacterial clearance, and reduced RSV viral load, suggesting a promising
immunomodulatory intervention.
In the clinical arm of the study, 16S rRNA sequencing of nasopharyngeal samples
from UK infants revealed that RSV infection, both alone and in co-infection with
rhinovirus (RV), significantly increased the relative abundance of pathogenic
Proteobacteria, particularly Moraxella. These shifts were accompanied by
heightened pro-inflammatory cytokine responses, including IL-6, IL-8, and TNF-α,
and elevated levels of anti-inflammatory cytokines such as IL-10 and TGF-β in the
RSV and RSV+RV groups
Together, the data highlight how RSV alters innate immune responses and reshapes
the airway microbiota, favouring pathobiont expansion and increased inflammation.
The use of B. subtilis spores represents a novel strategy to bolster macrophage
function and limit RSV-associated complications. These findings underscore the
5
importance of host-microbe interactions in determining infection outcomes and offer
insights into microbiota-targeted therapies.
Description
Keywords
Respiratory syncytial virus (RSV) • Streptococcus pneumoniae • Co-infection • Lower respiratory tract infections (infants) • Alveolar macrophages (AMQs) • Phagocytic dysfunction • M2-like polarisation • Inflammation • Bacterial dissemination • Bacillus subtilis spores • Immunomodulatory therapy • Murine models / in vitro / ex vivo • 16S rRNA sequencing • Nasopharyngeal microbiota • Proteobacteria / Moraxella • Pro-inflammatory cytokines (IL-6, IL-8, TNF-α) • Anti-inflammatory cytokines (IL-10, TGF-β) • Airway microbiota dysbiosis • Host–microbe interactions • Pathobiont expansion • RSV viral load reduction • Infant clinical samples • Microbiota-targeted therapies
